CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals.
CYD14
CYD15
dengue
monotypic
multitypic
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
18 05 2021
18 05 2021
Historique:
received:
06
11
2019
accepted:
18
03
2020
pubmed:
22
3
2020
medline:
3
7
2021
entrez:
22
3
2020
Statut:
ppublish
Résumé
The immune profile of dengue-experienced individuals is a determinant of dengue reinfection severity risk. Individuals with a single prior dengue infection (monotypic) are at highest risk for severe disease, while individuals with ≥ 2 prior dengue infections (multitypic) are at lower risk. The tetravalent dengue vaccine (CYD-TDV) has shown efficacy in the prevention of dengue in individuals with prior dengue infection. We estimated efficacy in individuals with monotypic or multitypic immune profiles. Participants enrolled in the immunogenicity subsets of 2 randomized placebo-controlled phase 3 studies (CYD14, NCT01373281; CYD15, NCT01374516) were classified as either monotypic or multitypic, based on measured baseline dengue plaque reduction neutralization test. Vaccine efficacy (VE) against symptomatic virologically confirmed dengue (VCD) was assessed over 25 months and against VCD hospitalization over 6 years. Of 3927 participants in the immunogenicity subsets, 496 and 257 in the CYD-TDV and placebo groups, respectively, were classified as monotypic immune, and 1227 and 612, respectively, as multitypic immune. VE against symptomatic VCD was 77.4% (95% CI, 56.4%-88.2%) for monotypic and 89.2% (95% CI, 71.5%-95.9%) for multitypic profiles, with corresponding absolute risk reductions (ARRs) of 4.48% (95% CI, 2.32%-6.65%) for monotypics and 1.67% (95% CI, .89%-2.46%) for multitypics. VE against hospitalized VCD was 75.3% (95% CI, 42.7%-90.2%) in monotypics and 81.2% (95% CI, 21.7%-96.8%) in multitypics, with ARRs of 0.95% (95% CI, .37%-1.53%) for monotypics and 0.18% (95% CI, .02%-.34%) for multitypics. CYD-TDV benefits individuals with monotypic and multitypic immune profiles. Larger public health benefit is expected to derive from the protection of individuals with a monotypic immune profile.
Sections du résumé
BACKGROUND
The immune profile of dengue-experienced individuals is a determinant of dengue reinfection severity risk. Individuals with a single prior dengue infection (monotypic) are at highest risk for severe disease, while individuals with ≥ 2 prior dengue infections (multitypic) are at lower risk. The tetravalent dengue vaccine (CYD-TDV) has shown efficacy in the prevention of dengue in individuals with prior dengue infection. We estimated efficacy in individuals with monotypic or multitypic immune profiles.
METHODS
Participants enrolled in the immunogenicity subsets of 2 randomized placebo-controlled phase 3 studies (CYD14, NCT01373281; CYD15, NCT01374516) were classified as either monotypic or multitypic, based on measured baseline dengue plaque reduction neutralization test. Vaccine efficacy (VE) against symptomatic virologically confirmed dengue (VCD) was assessed over 25 months and against VCD hospitalization over 6 years.
RESULTS
Of 3927 participants in the immunogenicity subsets, 496 and 257 in the CYD-TDV and placebo groups, respectively, were classified as monotypic immune, and 1227 and 612, respectively, as multitypic immune. VE against symptomatic VCD was 77.4% (95% CI, 56.4%-88.2%) for monotypic and 89.2% (95% CI, 71.5%-95.9%) for multitypic profiles, with corresponding absolute risk reductions (ARRs) of 4.48% (95% CI, 2.32%-6.65%) for monotypics and 1.67% (95% CI, .89%-2.46%) for multitypics. VE against hospitalized VCD was 75.3% (95% CI, 42.7%-90.2%) in monotypics and 81.2% (95% CI, 21.7%-96.8%) in multitypics, with ARRs of 0.95% (95% CI, .37%-1.53%) for monotypics and 0.18% (95% CI, .02%-.34%) for multitypics.
CONCLUSIONS
CYD-TDV benefits individuals with monotypic and multitypic immune profiles. Larger public health benefit is expected to derive from the protection of individuals with a monotypic immune profile.
Identifiants
pubmed: 32198515
pii: 5810750
doi: 10.1093/cid/ciaa304
pmc: PMC8130022
doi:
Substances chimiques
Antibodies, Viral
0
Dengue Vaccines
0
Vaccines, Combined
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1730-1737Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Lancet. 2014 Oct 11;384(9951):1358-65
pubmed: 25018116
Vaccine. 2019 Aug 14;37(35):4848-4849
pubmed: 30424888
Lancet Infect Dis. 2019 Jan;19(1):e31-e38
pubmed: 30195995
Am J Trop Med Hyg. 2013 May;88(5):962-970
pubmed: 23458954
N Engl J Med. 2015 Jan 8;372(2):113-23
pubmed: 25365753
BMC Infect Dis. 2016 Oct 7;16(1):546
pubmed: 27717314
PLoS Med. 2016 Nov 29;13(11):e1002181
pubmed: 27898668
J Infect Dis. 2013 Sep;208(6):1026-33
pubmed: 23776195
Nature. 2018 May;557(7707):719-723
pubmed: 29795354
N Engl J Med. 2018 Jul 26;379(4):327-340
pubmed: 29897841
N Engl J Med. 2015 Sep 24;373(13):1195-206
pubmed: 26214039
Science. 1988 Jan 29;239(4839):476-81
pubmed: 3277268
Vaccine. 2008 Aug 5;26(33):4113-9
pubmed: 18597906
Vector Borne Zoonotic Dis. 2009 Feb;9(1):87-92
pubmed: 18788903
IARC Sci Publ. 1987;(82):1-406
pubmed: 3329634
J Infect Dis. 2004 Mar 15;189(6):990-1000
pubmed: 14999601
Can J Infect Dis Med Microbiol. 2018 Sep 2;2018:2308095
pubmed: 30245759
Am J Trop Med Hyg. 1988 Jan;38(1):172-80
pubmed: 3341519
Viral Immunol. 2008 Jun;21(2):123-32
pubmed: 18476771
J Vector Borne Dis. 2014 Sep;51(3):153-64
pubmed: 25253207
PLoS Negl Trop Dis. 2018 Jun 28;12(6):e0006616
pubmed: 29953438
Am J Trop Med Hyg. 2007 Nov;77(5):910-3
pubmed: 17984352
N Engl J Med. 2016 Mar 24;374(12):1155-66
pubmed: 27007959